Trial Profile
A Multicenter Study to Evaluate the Efficacy and Safety of Tin Mesoporphyrin (Stannsoporfin) to Reduce the Need for Phototherapy in Term and Near Term Infants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Stannsoporfin (Primary)
- Indications Nutritional and metabolic diseases
- Focus Registrational; Therapeutic Use
- Sponsors InfaCare Pharmaceutical Corporation
- 22 Feb 2016 New trial record